← Leaderboards
Kam-Meng Tchou-Wong
New York University School Of Medicine
$3,861,790
Attributed
$3,861,790
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $451K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,861,790 · 8
By mechanism
R01$1,824,430 · 2
R21$1,204,037 · 3
P30$833,285 · 2
M01$38 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Collaborations”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$557,285,233
- David Heimbrook · Leidos Biomedical Research, Inc.$519,426,565
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$479,076,140
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Albert Lazzarini · California Institute Of Technology$382,990,355
Research focus
CollaborationsAnimalsEquipmentTumorTrainingBreathingHuman ResourcesSamplingServicesSourceResourcesResearch PersonnelResource SharingRouteStagingCommunitiesAntibodiesMemberResearch ActivityAnimal ModelChemopreventionCarcinogenesisLaboratory MouseAnimal Facility
Grant awards (20)
Experimental Pathology$163,041
P30 · FY2012 · CA · contact PI
Experimental Animal Facility$70,082
P30 · FY2012 · CA · contact PI
Development of cell-permeable antibodies for post-exposure treatment of ricin$214,335
R21 · FY2011 · AI · contact PI
Experimental Pathology$169,996
P30 · FY2011 · CA · contact PI
Experimental Animal Facility$66,709
P30 · FY2011 · CA · contact PI
Development of cell-permeable antibodies for post-exposure treatment of ricin$200,000
R21 · FY2010 · AI · contact PI
Experimental Pathology$178,943
P30 · FY2010 · CA · contact PI
Experimental Animal Facility$70,220
P30 · FY2010 · CA · contact PI
Experimental Animal Facility$72,867
P30 · FY2009 · CA · contact PI
Experimental Animal Facility$41,427
P30 · FY2008 · CA · contact PI
New Therapeutic Approach for Ricin-Induced Lung Injury$240,452
R21 · FY2007 · AI · contact PI
New Therapeutic Approach for Ricin-Induced Lung Injury$211,750
R21 · FY2006 · AI · contact PI
Chemoprevention of Carcinogen-Induced Lung Cancer$422,500
R01 · FY2005 · CA
Chemoprevention of Carcinogen-Induced Lung Cancer$422,500
R01 · FY2004 · CA
p53 Responses and Lung Cancer Risk$38
M01 · FY2004 · RR
Chemoprevention of Carcinogen-Induced Lung Cancer$422,083
R01 · FY2003 · CA
Role of H. Pylori Infection in Esophageal Adenocarcinoma$169,000
R21 · FY2003 · DK
Role of H. Pylori Infection in Esophageal Adenocarcinoma$168,500
R21 · FY2002 · DK
CJUN KINASE (JNK) PATHWAY IN SILICA INDUCED APOPTOSIS$282,792
R01 · FY2001 · ES
CJUN KINASE (JNK) PATHWAY IN SILICA INDUCED APOPTOSIS$274,555
R01 · FY2000 · ES